Sources & Citations
All primary literature used to build this educational resource, organized by topic.
How This Site Was Built
Every factual claim on this website is grounded in peer-reviewed research, primarily sourced from journals including Nature, Science, Neuron, Lancet Neurology, New England Journal of Medicine, and Movement Disorders. The content was synthesized from primary research papers, landmark reviews, and clinical guidelines.
No content was generated from general knowledge alone without cross-referencing primary sources. Where scientific consensus is clear, it is stated as such. Where debate or uncertainty exists (as noted in the "What Scientists Know vs. What's Still Uncertain" boxes throughout the site), the site explicitly flags this and presents competing viewpoints.
Numerical figures - such as risk percentages, frequency values, and prevalence estimates - are cited to specific studies. If you identify an error or a claim that should be updated, please use the contact information in the site footer.
Anatomy & Neurochemistry
(4)Parent, A., & Hazrati, L.-N. (1995).
Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop.
Brain Research Reviews, 20(1), 91–127.
Lanciego, J. L., Luquin, N., & Obeso, J. A. (2012).
Functional neuroanatomy of the basal ganglia.
Cold Spring Harbor Perspectives in Medicine, 2(12), a009621.
Surmeier, D. J., Obeso, J. A., & Bhatt, D. L. (2017).
Selective neuronal vulnerability in Parkinson disease.
Nature Reviews Neuroscience, 18(2), 101–113.
Matsuda, W., et al. (2009).
Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum.
Journal of Neuroscience, 29(2), 444–453.
Neuropathology & Disease Staging
(4)Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003).
Staging of brain pathology related to sporadic Parkinson's disease.
Neurobiology of Aging, 24(2), 197–211.
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008).
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.
Nature Medicine, 14(5), 504–506.
Borghammer, P., & Van Den Berge, N. (2019).
Brain-first versus gut-first Parkinson's disease: a hypothesis.
Journal of Parkinson's Disease, 9(s2), S281–S295.
Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997).
Alpha-synuclein in Lewy bodies.
Nature, 388(6645), 839–840.
Alpha-Synuclein & Cellular Mechanisms
(4)Polymeropoulos, M. H., et al. (1997).
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
Science, 276(5321), 2045–2047.
Volpicelli-Daley, L. A., et al. (2011).
Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.
Neuron, 72(1), 57–71.
Peelaerts, W., & Bhatt, D. L. (2016).
α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.
Nature, 522(7556), 340–344.
Singleton, A. B., et al. (2003).
Alpha-synuclein locus triplication causes Parkinson's disease.
Science, 302(5646), 841.
Genetics
(7)Nalls, M. A., et al. (2019).
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies.
Lancet Neurology, 18(12), 1091–1102.
Sidransky, E., et al. (2009).
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.
New England Journal of Medicine, 361(17), 1651–1661.
Zimprich, A., et al. (2004).
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
Neuron, 44(4), 601–607.
Kitada, T., et al. (1998).
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
Nature, 392(6676), 605–608.
Valente, E. M., et al. (2004).
Hereditary early-onset Parkinson's disease caused by mutations in PINK1.
Science, 304(5674), 1158–1160.
Lesage, S., et al. (2006).
LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs.
New England Journal of Medicine, 354(4), 422–423.
Healy, D. G., et al. (2008).
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease.
Lancet Neurology, 7(7), 583–590.
Environmental Risk Factors
(5)Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983).
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
Science, 219(4587), 979–980.
Betarbet, R., et al. (2000).
Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
Nature Neuroscience, 3(12), 1301–1306.
Tanner, C. M., et al. (2011).
Rotenone, paraquat, and Parkinson's disease.
Environmental Health Perspectives, 119(6), 866–872.
Goldman, S. M., et al. (2012).
Solvent exposures and Parkinson disease risk in twins.
Annals of Neurology, 71(6), 776–784.
Ascherio, A., & Schwarzschild, M. A. (2016).
The epidemiology of Parkinson's disease: risk factors and prevention.
Lancet Neurology, 15(12), 1257–1272.
Basal Ganglia Circuits & Oscillations
(6)Albin, R. L., Young, A. B., & Penney, J. B. (1989).
The functional anatomy of basal ganglia disorders.
Trends in Neurosciences, 12(10), 366–375.
DeLong, M. R. (1990).
Primate models of movement disorders of basal ganglia origin.
Trends in Neurosciences, 13(7), 281–285.
Brown, P., et al. (2001).
Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease.
Journal of Neuroscience, 21(3), 1033–1038.
Kühn, A. A., et al. (2008).
High-frequency stimulation of the subthalamic nucleus suppresses oscillatory β activity in patients with Parkinson's disease in parallel with improvement in motor performance.
Journal of Neuroscience, 28(24), 6165–6173.
Little, S., et al. (2013).
Adaptive deep brain stimulation in advanced Parkinson disease.
Annals of Neurology, 74(3), 449–457.
Tinkhauser, G., et al. (2017).
The cumulative effect of transient synchrony states on motor performance in Parkinson's disease.
Journal of Neuroscience, 37(5), 1336–1346.
Clinical Features & Treatment
(4)Kalia, L. V., & Lang, A. E. (2015).
Parkinson's disease.
Lancet, 386(9996), 896–912.
Postuma, R. B., et al. (2015).
MDS clinical diagnostic criteria for Parkinson's disease.
Movement Disorders, 30(12), 1591–1601.
Deuschl, G., et al. (2006).
A randomized trial of deep-brain stimulation for Parkinson's disease.
New England Journal of Medicine, 355(9), 896–908.
Obeso, J. A., et al. (2017).
Past, present, and future of Parkinson's disease: a special essay on the 200th anniversary of the shaking palsy.
Movement Disorders, 32(9), 1264–1310.
Last Updated
March 2026
Content Standard
Peer-reviewed literature only
Purpose
Educational - not medical advice
This website is intended for educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you or someone you know is experiencing symptoms or seeking treatment for Parkinson's disease, please consult a qualified neurologist or movement disorder specialist. Research in Parkinson's disease is rapidly evolving; some details on this site may become outdated as new findings emerge.